Biotechnology
OSE Immunotherapeutics To Host A KOL Webcast Dedicated To Lusvertikimab On September 2, 2026
Share
NANTES, France, August 28, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today announced that the Company will host a webcast with international experts in Inflammatory Bowel Diseases (IBD) to discuss its lead asset lusvertikimab on September 2, 2026, at noon ET (6pm CET).
The discussion will focus on IL-7R biology, promising results from the CoTiKis Phase 2 clinical trial in Ulcerative Colitis, future development plans in Chronic Pouchitis and will conclude with questions from the audience.
Invited experts are Laurent Peyrin-Biroulet, MD, PhD, (Nancy University Hospital, France) and Maia Kayal, MD, MS, (Icahn School of Medicine at Mount Sinai, New York). They will be joined by Marc Le Bozec, Chief Executive Officer and Aurore Morello, PhD, Chief Scientific Officer, OSE Immunotherapeutics.
KOL Webcast on Wednesday, September 2, 2026
6pm CET / noon ET
Live in English with optional French subtitles
Link to Webcast:
https://ose-immunotherapeutics.engagestream.euronext.com/2026-09-02-lusvertikimab
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on LinkedIn.
Contacts
OSE Immunotherapeutics: investors@ose-immuno.com
FP2COM (Media Relations): Florence Portejoie: fportejoie@fp2com.fr I +33 6 07 768 283
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
Attachment
Frequently Asked Questions
What is the OSE Immunotherapeutics webcast about?
The webcast will discuss OSE Immunotherapeutics' lead asset lusvertikimab, focusing on IL-7R biology, promising Phase 2 clinical trial results in Ulcerative Colitis, and future development plans in Chronic Pouchitis.
Who are the invited experts for the webcast?
The invited experts are Laurent Peyrin-Biroulet, MD, PhD (Nancy University Hospital, France) and Maia Kayal, MD, MS (Icahn School of Medicine at Mount Sinai, New York).
When and where can I watch the lusvertikimab webcast?
The webcast will be held on September 2, 2026, at noon ET (6pm CET). It will be live in English with optional French subtitles, accessible via a link on Euronext's platform.
First published on Fri, Aug 28, 2026
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Loading comments...